Evofem Biosciences | 8-K: FY2026 Q1 Revenue: USD 899 K
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q1, the actual value is USD 899 K.
EPS: As of FY2026 Q1, the actual value is USD -0.04.
Evofem Biosciences, Inc. announced its financial results for the three months ended March 31, 2026; however, the detailed financial results, including specific revenue, operational metrics, or cash flow figures for this period, are not provided within the text of this filing.
Outlook / Guidance
Evofem Biosciences, Inc. anticipates impacts from COGS reduction initiatives, future sales trends, cost-reduction initiatives, manufacturing efficiencies, and international market expansion. The company also expects to pursue additional financing or other strategic alternatives. It acknowledges significant risks including limited cash resources, dependence on new capital for operations, potential delays in regulatory approvals, and manufacturing and supply chain challenges.